Browse Articles

The authors looked at 5-FU resistant HeLa cells and the ability of an herbal extract to show anti-inflammatory properties.

Here, based on the identification of androgapholide as a potential therapeutic treatment against cancer, Alzheimer's disease, diabetes, and multiple sclerosis, due to its ability to inhibit a signaling pathway in immune system function, the authors sought ways to optimize the natural product human systems by manipulating its chemical structure. Through the semisynthesis of a natural product along with computational studies, the authors developed an understanding of the kinetic mechanisms of andrographolide and semisynthetic analogs in the context of Michael additions.

Osteosarcoma is a type of bone cancer that affects young adults and children. Early diagnosis of osteosarcoma is crucial to successful treatment. The current methods of diagnosis, which include imaging tests and biopsy, are time consuming and prone to human error. Hence, we used deep learning to extract patterns and detect osteosarcoma from histological images. We hypothesized that the combination of two different technologies (transfer learning and data augmentation) would improve the efficacy of osteosarcoma detection in histological images. The dataset used for the study consisted of histological images for osteosarcoma and was quite imbalanced as it contained very few images with tumors. Since transfer learning uses existing knowledge for the purpose of classification and detection, we hypothesized it would be proficient on such an imbalanced dataset. To further improve our learning, we used data augmentation to include variations in the dataset. We further evaluated the efficacy of different convolutional neural network models on this task. We obtained an accuracy of 91.18% using the transfer learning model MobileNetV2 as the base model with various geometric transformations, outperforming the state-of-the-art convolutional neural network based approach.

Here, recognizing that the immune response to cancer results in biomarkers that can be used to assess the immune status of cancer patients, the authors investigated the concentrations of key cytokines (TH1 and TH2 cytokines) in healthy controls and cancer patients. They identified significant changes in resting and activated cytokine profiles, suggesting that data of biomarkers such as these could serve as a starting point for further treatment with regard to a patient's specific immune profile.

The current five-year survival rate of metastasized prostate cancer is only 30% and occurs in every one in nine men. Researchers have shown that people with a type of dwarfism called Laron’s Syndrome are immune to cancer due to their low levels of insulin-like growth factor-1 (IGF-1). For this reason, experimentally modifying the level of IGF-1 could provide better insight into whether lowering the levels of IGF-1 in prostate cancer cell lines (e.g. PC-3) could be an effective treatment to reduce their rates of proliferation and migration and increase apoptosis. We selected three compounds, which researchers have shown decrease IGF-1 levels, to test and combine to determine which is the most promising.

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, with early diagnosis and treatment challenges. When any of the genes KRAS, SMAD4, TP53, and BRCA2 are heavily mutated, they correlate with PDAC progression. Cellular stress, partly regulated by the gene SERPINA6, also correlates with PDAC progression. When SERPINA6 is highly expressed, corticosteroid-binding globulin inhibits the effect of the stress hormone cortisol. In this study, the authors explored whether there is an inverse correlation between the expression of SERPINA6 and PDAC-linked genes.

Here the authors sought to better understand glioma, cancer that occurs in the glial cells of the brain with gene expression profile analysis. They considered the expression of complement system genes across the transcriptional and IDH-mutational subtypes of low-grade glioma and glioblastoma. Based on their results of their differential gene expression analysis, they found that outcomes vary across different glioma subtypes, with evidence suggesting that categorization of the transcriptional subtypes could help inform treatment by providing an expectation for treatment responses.

With disruption of DNA repair pathways pertinent to the timeline of cancer, thorough evaluation of mutations relevant to DNA repair proteins is crucial within cancer research. One such mutation includes S815L PMS2 - a mutation that results in significant decrease of DNA repair function by PMS2 protein. While mutation of PMS2 is associated with significantly increased colorectal and endometrial cancer risk, much work is left to do to establish the functional effects of the S815L PMS2 mutation in ovarian cancer progression. In this article, researchers contribute to this essential area of research by uncovering the tumor-progressive effects of the S815L PMS2 mutation in the context of ovarian cancer cell lines.

This study follows the process of single-cloning and the growth of a homogeneous cell population in a superficial environment over the course of six weeks with the end goal of showing which of five tumor growth models commonly used to predict heterogeneous cancer cell population growth (Exponential, Logistic, Gompertz, Linear, and Bertalanffy) would also best exemplify that of homogeneous cell populations.

In this study, Imani et al. investigate whether a new proprietary herbal formulation, HF1, can inhibit expression of immune suppressor protein PD-L1. PD-L1 is a transmembrane protein that can be expressed by cancer cells to assist in their ability to avoid attacks from the immune system. Work from this study demonstrates that HF1 treatment can reduce expression of PD-L1 in cultured cancer cells, implicating HF1 as a potential new cancer therapy.